Towada Products · New Delhi, India · Last updated:
Carfilzomib is a second-generation proteasome inhibitor used for relapsed or refractory multiple myeloma. Towada Products exports it from New Delhi, India, supplying Carfilnat and Carzomib in the 60mg strength to licensed buyers in Southeast Asia, the CIS region, the Middle East and select markets in Europe and Africa. Pricing is on enquiry.
Carfilzomib is a second-generation proteasome inhibitor. It binds the proteasome irreversibly, blocking the breakdown of proteins that myeloma cells need to keep under control, which leads to their death.
It is approved for relapsed or refractory multiple myeloma in patients who have received one or more prior lines of therapy, in combination with dexamethasone, with lenalidomide and dexamethasone, or with daratumumab and dexamethasone, and in some countries as a single agent. It is an intravenous infusion given by healthcare professionals. The originator brand is Kyprolis.
Carfilzomib is supplied as a powder in a single-use vial and is usually stored refrigerated at 2°C to 8°C, so shipments need temperature-controlled packaging; confirm the storage condition printed on the brand you order. Bortezomib, the first proteasome inhibitor, and lenalidomide are also in our catalog. Tell us the vial strength, quantity and destination when you enquire, and whether you need a temperature data logger.
Carfilzomib is a prescription medicine, and whether it is suitable for a patient is a decision for the treating doctor. This page describes the medicine for trade buyers; it is not medical advice.
Every carfilzomib product page on this site. "Listed for" is the use given in our catalog. Availability is confirmed when you enquire.
| Product | Composition | Listed for |
|---|---|---|
| Carfilnat 60mg | Carfilzomib (60mg) | Multiple myeloma |
| Carzomib 60mg | Carfilzomib (60mg) | Multiple myeloma |
Export markets we serve: Southeast Asia, the CIS region, the Middle East and select markets in Europe and Africa. See our export markets →
Tell us which documents your regulator or customs broker needs and we will confirm what applies to the product you are ordering.
Carfilzomib is a second-generation proteasome inhibitor used for relapsed or refractory multiple myeloma. It is a prescription medicine, and whether it is suitable for a patient is a decision for the treating doctor.
Our catalog has 2 carfilzomib product pages in the 60mg strength, from 2 brands: Carfilnat and Carzomib. The table on this page links to each product page; availability is confirmed when you enquire.
We ship from New Delhi by international courier or air cargo to licensed buyers in Southeast Asia, the CIS region, the Middle East and select markets in Europe and Africa, and have country pages for the Philippines, Russia, Kazakhstan, Uzbekistan, Iraq, Saudi Arabia and Brazil. Whether carfilzomib can be imported, and by whom, is decided by the destination country's medicines regulator, so tell us the country and we will confirm what is possible. Every country we cover is listed on our export markets page.
Each shipment travels with a commercial invoice, a packing list and a courier or air waybill. We provide a Certificate of Analysis (CoA) for the batch and, where it is available for the product and the destination country requires it, a Certificate of Pharmaceutical Product (CoPP). A certificate of origin can be arranged on request.
Use the enquiry form on this page, WhatsApp +91 99995 62955 or email H.S.Gandhi@towadaproducts.in. Tell us the brand, strength, quantity and destination country, and we will reply with availability and a formal quotation.
This page is general information for trade buyers. It is not medical advice. Import rules differ by country and change over time; confirm the current requirements with your national medicines regulator before ordering.
Tell us the brand, strength, quantity and destination country. Pricing is confirmed in a formal quote. Prefer WhatsApp? Message +91 99995 62955.
Plain answers to the questions importers ask before ordering medicines from India.
